On 2024-11-14, Achilles Therapeutics PLC Sponsored ADR (ACHL) announced earnings per share of $-0.48 for the fiscal quarter ending 2024-09-30, missing the average analyst estimate of $-0.41.
Note: Earnings figures are calculated as diluted earnings per share before non-recurring items and including employee stock options expenses.
| Announcement Date | Fiscal Quarter End | Estimated EPS | Actual EPS |
|---|---|---|---|
| 2024-11-14 | 2024-09-30 | $-0.41 | $-0.48 |
| 2024-08-14 | 2024-06-30 | $-0.41 | $-0.41 |
| 2024-05-08 | 2024-03-31 | $-0.46 | $-0.30 |
| 2024-04-04 | 2023-12-31 | -- | $-0.46 |
| 2023-11-13 | 2023-09-30 | $-0.38 | $-0.42 |
| 2023-08-04 | 2023-06-30 | $-0.40 | $-0.42 |
| 2023-05-10 | 2023-03-31 | $-0.41 | $-0.44 |
| 2023-03-07 | 2022-12-31 | $-0.42 | $-0.61 |
| 2022-11-08 | 2022-09-30 | $-0.55 | $-0.32 |
| 2022-08-09 | 2022-06-30 | $-0.57 | $-0.44 |
| 2022-05-10 | 2022-03-31 | $-0.51 | $-0.45 |
| 2022-03-01 | 2021-12-31 | $-0.39 | $-0.45 |
| 2021-11-09 | 2021-09-30 | $-0.49 | $-0.34 |
| 2021-08-10 | 2021-06-30 | $-0.53 | $-0.45 |
| 2021-05-11 | 2021-03-31 | $-3.04 | $-8.38 |